静脉瑞利珠单抗治疗需机械通气的重症COVID-19住院患者:3期多中心开放标签随机对照试验
该3期多中心开放标签随机对照试验纳入31家医院需有创或无创机械通气的重症COVID-19成人患者,按2:1随机接受静脉瑞利珠单抗联合最佳支持治疗(BSC)或单用BSC,瑞利珠单抗按体重于第1、5、10、15天给药。主要终点29天全因死亡生存率在瑞利珠单抗联合BSC组为58%,BSC组为60%(风险差-0.0205,95%CI -0.1703至0.1293,单侧p=0.61),无显著差异。瑞利珠单抗联合BSC组感染和侵染(57% vs 36%)及血管疾病(31% vs 18%)更常见,5例严重不良事件被认为与瑞利珠单抗相关。作者认为,尽管缺乏疗效,该研究显示C5抑制可在重症患者中实现,对未来补体治疗研究有价值。
要点
- 在需有创或无创机械通气的重症COVID-19患者中,瑞利珠单抗联合BSC组29天生存率58%,BSC组60%(风险差-0.0205,95%CI -0.1703至0.1293,单侧p=0.61)。
- 瑞利珠单抗联合BSC未改善生存或其他次要结局,试验因无效在期中分析时终止。
- 瑞利珠单抗联合BSC组感染和侵染(73/127,57% vs 24/67,36%)及血管疾病(39/127,31% vs 12/67,18%)较BSC组更常见。
- 5例严重不良事件被认为与瑞利珠单抗相关:菌血症、血小板减少、食管出血、隐球菌性肺炎和发热,各1例。
- 作者认为,该研究显示C5抑制可在重症患者中实现,对未来危重症补体治疗研究有价值。
适用人群与场景
- 年龄≥18岁、确诊SARS-CoV-2感染需住院、需有创或无创机械通气、经CT或X线证实严重肺炎、急性肺损伤或急性呼吸窘迫综合征的成人患者。
- 来自法国、日本、西班牙、英国和美国的31家医院。
诊断标准与关键阈值
- 主要疗效终点为意向治疗(ITT)人群第29天全因死亡生存率。
处置流程与药物剂量
- 瑞利珠单抗按体重静脉给药,于第1、5、10、15天给药,联合最佳支持治疗(BSC)。
- 对照组单用BSC。
研究设计与关键结果
- 3期多中心开放标签随机对照试验(ALXN1210-COV-305),2020年5月10日至2021年1月13日纳入202例患者,随机2:1接受瑞利珠单抗联合BSC或BSC;ITT人群201例(瑞利珠单抗联合BSC组135例,BSC组66例)。
- 瑞利珠单抗联合BSC组96例(71%)男性、39例(29%)女性,平均年龄63.2岁(SD 13.23);BSC组43例(65%)男性、23例(35%)女性,平均年龄63.5岁(SD 12.40)。
- 基线时有创机械通气:瑞利珠单抗联合BSC组113/135例(84%),BSC组53/66例(80%)。
- 基于多重插补的总生存率:瑞利珠单抗联合BSC组58%,BSC组60%(Mantel-Haenszel分析:风险差-0.0205;95%CI -0.1703至0.1293;单侧p=0.61)。
- 安全性人群:瑞利珠单抗联合BSC组127例中113例(89%)和BSC组67例中56例(84%)发生治疗中出现的不良事件。
- 感染和侵染:瑞利珠单抗联合BSC组73例(57%) vs BSC组24例(36%);血管疾病:瑞利珠单抗联合BSC组39例(31%) vs BSC组12例(18%),瑞利珠单抗联合BSC组更常见。
- 5例患者发生被认为与瑞利珠单抗相关的严重不良事件:菌血症、血小板减少、食管出血、隐球菌性肺炎和发热,各1例。
证据类型、等级与局限
- 证据类型:3期多中心开放标签随机对照试验。
- 试验因无效在期中分析时终止。
- 作者认为,尽管缺乏疗效,该研究显示C5抑制可在重症患者中实现,对未来危重症补体治疗研究有价值。
对床旁实践的改变
- 瑞利珠单抗联合BSC未改善需机械通气的重症COVID-19患者的生存或其他次要结局,试验因无效终止。
- 瑞利珠单抗联合BSC组感染和侵染及血管疾病较BSC组更常见;5例严重不良事件被认为与瑞利珠单抗相关。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: The complement pathway is a potential target for the treatment of severe COVID-19. We evaluated the safety and efficacy of ravulizumab, a terminal complement C5 inhibitor, in patients hospitalised with severe COVID-19 requiring invasive or non-invasive mechanical ventilation.
METHODS: This phase 3, multicentre, open-label, randomised controlled trial (ALXN1210-COV-305) enrolled adult patients (aged ≥18 years) from 31 hospitals in France, Japan, Spain, the UK, and the USA. Eligible patients had a confirmed diagnosis of SARS-CoV-2 that required hospitalisation and either invasive or non-invasive mechanical ventilation, with severe pneumonia, acute lung injury, or acute respiratory distress syndrome confirmed by CT scan or x-ray. We randomly assigned participants (2:1) to receive intravenous ravulizumab plus best supportive care (BSC) or BSC alone using a web-based interactive response system. Randomisation was in permuted blocks of six with stratification by intubation status. Bodyweight-based intravenous doses of ravulizumab were administered on days 1, 5, 10, and 15. The primary efficacy endpoint was survival based on all-cause mortality at day 29 in the intention-to-treat (ITT) population. Safety endpoints were analysed in all randomly assigned patients in the ravulizumab plus BSC group who received at least one dose of ravulizumab, and in all randomly assigned patients in the BSC group. The trial is registered with ClinicalTrials.gov, NCT04369469, and was terminated at interim analysis due to futility.
FINDINGS: Between May 10, 2020, and Jan 13, 2021, 202 patients were enrolled in the study and randomly assigned to ravulizumab plus BSC or BSC. 201 patients were included in the ITT population (135 in the ravulizumab plus BSC group and 66 in the BSC group). The ravulizumab plus BSC group comprised 96 (71%) men and 39 (29%) women with a mean age of 63·2 years (SD 13·23); the BSC group comprised 43 (65%) men and 23 (35%) women with a mean age of 63·5 years (12·40). Most patients (113 [84%] of 135 in the ravulizumab plus BSC group and 53 [80%] of 66 in the BSC group) were on invasive mechanical ventilation at baseline. Overall survival estimates based on multiple imputation were 58% for patients receiving ravulizumab plus BSC and 60% for patients receiving BSC (Mantel-Haenszel analysis: risk difference -0·0205; 95% CI -0·1703 to 0·1293; one-sided p=0·61). In the safety population, 113 (89%) of 127 patients in the ravulizumab plus BSC group and 56 (84%) of 67 in the BSC group had a treatment-emergent adverse event. Of these events, infections and infestations (73 [57%] vs 24 [36%] patients) and vascular disorders (39 [31%] vs 12 [18%]) were observed more frequently in the ravulizumab plus BSC group than in the BSC group. Five patients had serious adverse events considered to be related to ravulizumab. These events were bacteraemia, thrombocytopenia, oesophageal haemorrhage, cryptococcal pneumonia, and pyrexia (in one patient each).
INTERPRETATION: Addition of ravulizumab to BSC did not improve survival or other secondary outcomes. Safety findings were consistent with the known safety profile of ravulizumab in its approved indications. Despite the lack of efficacy, the study adds value for future research into complement therapeutics in critical illnesses by showing that C5 inhibition can be accomplished in severely ill patients.
FUNDING: Alexion, AstraZeneca Rare Disease.
参考来源
- Annane D, Pittock SJ, Kulkarni HS, et al. Intravenous ravulizumab in mechanically ventilated patients hospitalised with severe COVID-19: a phase 3, multicentre, open-label, randomised controlled trial. Lancet Respir Med. 2023. PMID: 36958364. doi:10.1016/S2213-2600(23)00082-6
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。